etectRx™ Inc., an early-stage digital health company, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,292,642 for an “Electronic Medication Compliance Monitoring System and Associated Methods.”
GAINESVILLE, Fla. (June 10, 2019) – etectRx™ Inc., an early-stage digital health company, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,292,642 for an “Electronic Medication Compliance Monitoring System and Associated Methods.” The patent covers an ingestible electronic system and methods for recording and tracking a patient’s adherence to a medication. etectRx has exclusive worldwide rights to the patented technology. The company has also received a notice of allowance and issue notification for U.S. Patent 10,321,849 for a “System for Ingestion Event Monitoring and Method for Detecting Ingestion Events with High Accuracy.”
These patents are part of a growing intellectual property portfolio of pending and granted patents that cover etectRx’s unique and proprietary technology in the U.S. and major international markets. They will also enable the commercialization of new products, services, and platform technologies to serve a broad range of markets.
etectRx is developing an ingestible event marker (the ID-Cap™ System), which gives clinicians and researchers the ability to accurately track and manage patients’ medication adherence on a per-dose basis. This proprietary technology has a unique mode of action. The ID-Cap System uses a novel ingestible sensor (the ID-Tag), which is delivered within a standard, hard gelatin capsule shell (the ID-Capsule). The ID-Tag is powered by stomach fluid and emits very low-power digital messages from within the patient each time an ID-Capsule is ingested. The messages are transmitted to a wearable reader (the ID-Cap Reader) and can be forwarded to the patient’s smartphone through a mobile application (the ID-Cap App).
“We are confident that these additional patents will broadly protect etectRx’s technology and provide our products with long-term market value,” said Harry J. Travis, president & CEO of etectRx. “These patents are important assets in etectRx’s intellectual property portfolio covering the ID-Cap System and our unique methods for monitoring patient adherence to medications.”
###
About etectRx, Inc.
etectRx is a privately held digital health company seeking to advance patient medication adherence and improve medication ingestion tracking technology. etectRx’s flagship product, the ID-Cap System, is an ingestible event marker that is comprised of a gelatin capsule containing a wireless ingestible sensor, which transmits signals to a wearable reader and then to a smartphone-based app and secure cloud-based server to enable reliable tracking of ingestion events.
etectRx submitted a premarket notification (510(k)) application with the U.S. Food and Drug
Administration (FDA) for its ID-Cap System as an ingestible event marker in late 2018 and
anticipates FDA clearance for marketing in 2019. The ID-Cap System is currently only
available for investigational use in IRB-approved clinical studies.
To learn more about etectRx, visit https://etectrx.com.
